Patients with advanced cancers (stages III and IV) had higher SOD activities than those with stage 0, I, and II cancers, significantly so at baseline (670 U/mL vs. 567 U/mL, p = 0.012) and at 72 h (655 U/mL vs. 564 U/mL, p = 0.033). This evidence concerns the gene SOD1 and cancer.